Ewa Karpińska

Ewa Karpińska

Auto-generated profile, based on publicly available information

Ewa Karpińska

Department of Infectious Diseases, Hepatology and Liver Transplantation, Pomeranian Medical University, 70-204 Szczecin, Poland

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Robert FlisiakRobert Flisiak
Robert Flisiak
Dorota Zarębska-MichalukDorota Zarębska-Michaluk
Dorota Zarębska-Michaluk
EJEwa Janczewska
Ewa Janczewska
TŁTadeusz Łapiński
Tadeusz Łapiński
MRMagdalena Rogalska
Magdalena Rogalska
JJJerzy Jaroszewicz
Jerzy Jaroszewicz
(1) Background: Treatment of hepatitis C virus (HCV) infections with direct-acting antivirals (DAA) has demonstrated high efficacy and an excellent safety profile. The cured patients showed a sustained virological response and improved liver function, but also a continued risk of hepatocellular carcinoma (HCC) during the 2–3 years of follow-up after treatment; (2) Methods: A total of 192 patients out of 209 of the primary AMBER study were analyzed five years after treatment with ombitasvir/paritaprevir/ritonavir with or without dasabuvir and with or without ribavirin. Results: We confirmed that HCV clearance after DAA treatment is stable regardless of baseline liver fibrosis. We found that sustained virologic response is associated with a gradual but significant reduction in liver stiffness over 5 years. Liver function improved during the first 2 years of follow-up and remained stable thereafter. The risk of death due to HCC as well as death due to HCV persists through 5 years of follow-up after successful DAA treatment. However, in non-cirrhotic patients, it appears to clear up 3 years after treatment; (3) Conclusions: Monitoring for more than 5 years after curing HCV infection is necessary to assess the long-term risk of possible development of HCC, especially in patients with cirrhosis of the liver.

9 February 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HWHanna Wiśniewska
Hanna Wiśniewska
Karolina Skonieczna-ŻydeckaKarolina Skonieczna-Żydecka
Karolina Skonieczna-Żydecka
MPMiłosz Parczewski
Miłosz Parczewski
JNJolanta Niścigorska-Olsen
Jolanta Niścigorska-Olsen
EKEwa Karpińska
Ewa Karpińska
MWMarta Malgorzata Wawrzynowicz-Syczewska
Marta Malgorzata Wawrzynowicz-Syczewska
Liver injury—expressed as elevated liver enzymes—is common in patients with COVID-19. Little is known about the potential mechanisms of liver damage by SARS-CoV-2. A direct cytopathic effect on hepatocytes as well as injury related to hypoxia or hepatotoxicity are being considered. The aim of the study was to compare the clinical characteristic of COVID-19 disease in patients with normal and abnormal liver enzymes activity. A group of 150 patients with COVID-19, hospitalized in our center, was analyzed. Patients with the known liver comorbidities were excluded (n = 15). Clinical features and laboratory parameters were compared between patients with normal and abnormal aminotransferase values. Liver injury expressed as any alanine aminotransferase (ALT) elevation was noted in 45.6% of patients hospitalized due to COVID-19. The frequencies of aspartate aminotransferase (AST) elevation were lower. It was noted that elevated ALT/AST unfavorably affected other parameters related to liver function such as albumin level; gamma-glutamyl transpeptidase (GGTP); and partly, ALP activity and influenced inflammation-related parameters. The most probable cause of mild hepatitis during COVID-19 was anoxia and immune-mediated damage due to the inflammatory response following SARS-CoV-2 infection. A direct cytopathic effect of SARS-CoV-2 on hepatocytes, albeit less probable, can be considered as well. The use of potentially hepatotoxic drugs may contribute to liver damage.

1 August 2009
Verified
Journal Article
Closed access
MWMarta Malgorzata Wawrzynowicz-Syczewska
Marta Malgorzata Wawrzynowicz-Syczewska
EKEwa Karpińska
Ewa Karpińska
KJKrzysztof Jurczyk
Krzysztof Jurczyk
LLLukasz Laurans
Lukasz Laurans
ABAnna Boroń-Kaczmarska
Anna Boroń-Kaczmarska

1 January 2014 in Annals of Transplantation
Verified
Journal Article
Closed access
PDF file
MWMarta Malgorzata Wawrzynowicz-Syczewska
Marta Malgorzata Wawrzynowicz-Syczewska
ŁSŁukasz Socha
Łukasz Socha
EKEwa Karpińska
Ewa Karpińska
KJKrzysztof Jurczyk
Krzysztof Jurczyk
ŁLŁukasz Laurans
Łukasz Laurans
MLMarta Lachtara
Marta Lachtara
Recurrence of hepatitis C virus (HCV) infection after liver transplantation is inevitable and decreases survival. Graft loss due to recurrent HCV occurs in 25% to 30% of patients. The recommended AASLD treatment is PEG-IFN, with or without ribavirin, but some patients might be not eligible for this treatment. An alternative antiviral agent is silibinin (SIL). In vitro silibinin stops replication, probably by inhibiting HCV RNA polymerase. We present the cases of 2 patients with severe recurrent HCV infection who received intravenous silibinin (IV SIL) as a "rescue therapy". In the first patient with cholestatic fibrosing hepatitis, HCV RNA became undetectable. We also noted significant viremia reduction, and improvement in laboratory results and clinical presentation in the second patient. Administration of IV SIL resulted in a rapid decrease of HCV viremia. In post-transplant patients with HCV recurrence who are not eligible for standard antiviral treatment, IV SIL can be considered as an alternative, but further investigations are necessary to establish treatment protocols.

1 August 2002
Verified
Journal Article
Closed access
MWMarta Malgorzata Wawrzynowicz-Syczewska
Marta Malgorzata Wawrzynowicz-Syczewska
ALAgnieszka Leonciuk
Agnieszka Leonciuk
KJKrzysztof Jurczyk
Krzysztof Jurczyk
EKEwa Karpińska
Ewa Karpińska
ABAnna Boroń-Kaczmarska
Anna Boroń-Kaczmarska

1 January 2005
Verified
Journal Article
Closed access
EKEwa Karpińska
Ewa Karpińska
MWMarta Wawrzynowicz-Syczewska
Marta Wawrzynowicz-Syczewska
KJKrzysztof Jurczyk
Krzysztof Jurczyk
IMIzabella Morańska
Izabella Morańska
WUWaldemar Urbanowicz
Waldemar Urbanowicz
ABAnna Boroń-Kaczmarska
Anna Boroń-Kaczmarska